News

The company will file the application in the third quarter of 2007 for the drug, which is for the treatment of chronic lymphocytic leukemia (CLL). “Treanda offers a

The company’s clinical trial results showed that the drug candidate CRx-150 did not significantly decrease inflammation. Alexis Borisy, president and CEO of CombinatoRx, said the level of activity

Spheramine is being developed by Titan in collaboration with Bayer Schering Pharma. Results from the study are expected to be available in the third quarter of 2008. According

The trial was designed to evaluate the safety and efficacy of ispinesib in the second- or third-line treatment of patients with locally advanced or metastatic breast cancer whose

The patients enrolled in this study were using metformin with or without thiazolidinediones. The results showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for six

The scientists from Oxford University, in collaboration with the US National Institutes of Health, said that the cells are expected to serve as an improved model for human

The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. The trial showed that approximately 40% of the evaluable patients in the study

A study evaluating Velcade, melphalan and prednisone demonstrated a complete response (CR) rate of 43%, the strongest rate ever reported for a melphalan-prednisone combination therapy, Millennium said. At

In addition, new data from a phase I study showed that sunitinib malate is active and generally well-tolerated in combination with a standard chemotherapy regimen, Folfiri, in previously